China approves ORPATHYS-TAGRISSO combo for lung cancer with MET amplification

China's National Medical Products Administration has approved HUTCHMED's ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) with MET amplification after progression on EGFR tyrosine kinase inhibitor therapy. This approval, based on Phase III SACHI trial data demonstrating a 66% reduction in disease progression risk and a median progression-free survival of 8.2 months, establishes the first all-oral treatment option for this patient population. The regulatory milestone, which marks ORPATHYS's third indication in China, triggers an $11 million milestone payment to HUTCHMED from AstraZeneca, addressing a significant unmet need for patients experiencing MET amplification post-TKI treatment.

Analysis

HUTCHMED has secured a significant regulatory win with China's NMPA approving its ORPATHYS (savolitinib) in combination with AstraZeneca's TAGRISSO for a specific subset of non-small cell lung cancer (NSCLC) patients. The approval is underpinned by robust Phase III SACHI trial data, which demonstrated a 66% reduction in the risk of disease progression and a near-doubling of median progression-free survival to 8.2 months compared to 4.5 months for standard chemotherapy. Critically, this combination represents the first all-oral treatment for this patient population, addressing a notable unmet need. The safety profile was comparable to chemotherapy, with no new signals observed. The commercial opportunity is substantial, targeting the 15-50% of EGFR TKI-treated patients who develop MET amplification. The approval immediately triggers an $11 million milestone payment to HUTCHMED from its partner AstraZeneca, which markets both drugs in China, providing a direct boost to HUTCHMED's fundamentals.

Key Decisions for Investors

• For HUTCHMED investors, this approval serves as a key value inflection point, de-risking the ORPATHYS asset and providing immediate non-dilutive capital, which should be viewed as a strong positive catalyst for the stock.
• Investors in AstraZeneca should see this as a strategic enhancement to their China oncology portfolio, reinforcing the market position of their key drug TAGRISSO, though the direct financial impact is marginal for a company of its scale.
• The primary focus for investors should now shift to monitoring the commercial launch and adoption rates in China, as the successful penetration of this clearly defined patient population will determine the long-term revenue contribution from this new indication.